Literature DB >> 10689840

[The anesthetic management for elective or emergent cesarean section in patients with intracranial arteriovenous malformation].

I Hatsukari1, H Nagasaka, M Tsuchiya, M Taguchi.   

Abstract

Subarachnoid hemorrhage secondary to ruptured intracranial arteriovenous malformation (AVM) during pregnancy, although rare, is a grave complication. We experienced 3 patients with AVM for cesarean section. Case 1: A 24-year-old woman suffered sudden vomiting and headache during the 22nd week of her first pregnancy. She was diagnosed as having the intracranial hemorrhage due to AVM. Because the patient was bleeding again at 29th week of pregnancy, emergency operation was performed. Her neurological symptom improved. Cesarean section was performed under general anesthesia at 34th week of pregnancy. Case 2: A 42-year-old woman of her first pregnancy had past history of subarachnoid hemorrhage due to AVM at the ages of 23, 28, 29 and 36. The malformation was not corrected surgically. Her neurological status was normal. Cesarean section was performed under spinal anesthesia. Case 3: A 29-year-old woman suffered sudden hemiplegia, vomiting and headache during the 40th week of her first pregnancy. She was diagnosed as having intracranial hemorrhage. Cesarean section immediately followed by the removal of an intra cranial hematoma under general anesthesia. Better perinatal outcome is expected when AVM rerupture is prevented by first performing cesarean section.

Entities:  

Mesh:

Year:  2000        PMID: 10689840

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

1.  Remifentanil use for cesarean section in a patient with intracranial re-ruptured arteriovenous malformation.

Authors:  Eiko Onishi; Akiko Kojima; Toshio Saishu; Shin Kurosawa
Journal:  J Anesth       Date:  2011-12-11       Impact factor: 2.078

2.  Pre-existing, incidental and hemorrhagic AVMs in pregnancy and postpartum: Gestational age, morbidity and mortality, management and risk to the fetus.

Authors:  Xianli Lv; Peng Liu; Youxiang Li
Journal:  Interv Neuroradiol       Date:  2015-12-15       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.